Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00808925
Other study ID # SHEBA-08-5524-YE-CTIL
Secondary ID
Status Terminated
Phase N/A
First received December 15, 2008
Last updated December 18, 2013
Start date January 2009
Est. completion date July 2013

Study information

Verified date December 2013
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Interventional

Clinical Trial Summary

There is growing evidence to conclude that part of the cascade leading to heatstroke is related to an inflammatory reaction triggered by the heat stress. The reduced ability to sustain heat stress - "heat intolerance" is also attributed to over-expression of inflammatory cytokines. Acclimation to heat improves human sustainability to heat and is a leading protective factor against heat stroke. The investigators hypothesize that the lower stress encountered during the process of acclimation to heat will be reflected by an over-ride in the expression of anti-inflammatory over the pro-inflammatory cytokines. This, in turn will attenuate the pathological cascade leading to heat stroke.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date July 2013
Est. primary completion date April 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria:

- age:18-25

- medically screened (healthy)

Exclusion Criteria:

- BMI over 22 kg/m2

- systolic blood pressure over 120 mmHg

- any febrile illness during the last week preceding the study

- any skin disease

- diabetes

- any heart conditions.

Study Design

Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
exposure to heat
Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.

Locations

Country Name City State
Israel Heller Institute of Medical Reachearch, Sheba Medical Center Tel Hashomer

Sponsors (2)

Lead Sponsor Collaborator
Prof. Yoram Epstein Medical Corps, Israel Defense Force

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Investigating the variability in the levels of different cytokine and the kinetics in cytokine levels during the process of acclimation to heat. 12 days No